Introduction
Hereditary predisposition accounts for 5-10% of all breast cancer (BC) cases (1,2), 15-20% of which are caused by mutations in the two major susceptibility genes: BRCA1 (MIM# 113705) and BRCA2 (MIM# 600185) (3) . More than 3500 distinct DNA changes in BRCA1 and BRCA2 sequences have been characterized in the reference databases (the Breast Cancer Core Database, BIC database and the Universal Mutation Database) (4, 5) , which are spread throughout their entire coding and flanking intronic regions. Only a small number of DNA variations are predominant in some specific ethnic groups as a consequence of a founder effect originated in a common ancestor (6) . Spanish population has shown a specific distribution of founder mutations reflecting the existence of population substructures in the Iberian Peninsula (7) (8) (9) (10) .
According to the BIC database, c.2808_2811del (p.Ala938Profs*21) is the second most reported frameshift BRCA2 mutation and the most prevalent mutation in Castilla y León, Spain (9) (10) (11) . This mutation has been reported in almost all Western European countries (12) and in African women with premenopausal BC (13) . Furthermore, the same mutation was found de novo in a BC case that suggested that these BRCA2 nucleotides were a mutation hotspot (14) .
Knowledge of the molecular origin of a mutation is critical to the understanding of human disease and evolution. Mutations in humans may be caused by exogenous mutagens or endogenous mechanisms (15) . Mutation rates can vary substantially across genomic regions, so that they exceed the average rate at some extremely mutable sites (mutation hotspots) (16) . Moreover, a previous study of the secondary structure of the DNA showed that the most hypermutable bases of the TP53 tumor suppressor gene were located in stable DNA stem-loop arrangements (17) . In this study, we set out to verify the presence of a possible unique founder effect of mutation c.2808_2811del or several independent mutational events occurred. This feature could be relevant in populations where the prescreening of specific mutation panels is a cost-effective strategy prior the BRCA1/BRCA2 mutation scanning. To address this issue, we performed haplotype analysis in the region surrounding the BRCA2 gene in 51 carrier families and then, we estimated the mutation age according to each haplotype and its geographical distribution. Moreover, a DNA secondary structure prediction and a random mutagenesis experiment were performed to identify mutational hotspots.
Materials and methods

Patients
Fifty-one unrelated families harboring BRCA2-c.2808_2811del from 10 Spanish familial cancer centers were included in this study (Table I) . Patient data regarding age of diagnosis, current age or age at death, familial cancer history and geographical origin were collected. After written informed consent, DNA samples were obtained from at least one affected member of each family. To date, 23 c.2808_2811del families were identified in the Instituto de Biología y Genética Molecular laboratory after mutation scanning by conformational sensitive gel electrophoresis or heteroduplex analysis by capillary array electrophoresis and confirmed by DNA sequencing as described elsewhere (18, 19) , but only 16 affected families were included in this study. The screening of the rest of the patients was performed at the respective participant laboratories with different methods (10) . All mutation carriers from other laboratories were further confirmed at the Instituto de Biología y Genética Molecular. The control population (75 anonymous and unrelated samples) used was obtained from the National DNA Bank, a collection of representative DNA samples of the Spanish population (20) . This study was approved by the Ethics committee of the Faculty of Medicine, University of Valladolid (Spain).
Genotyping
A total of 221 DNA samples representing 51 index cases, 95 family members and 75 controls were typed with 7 short tandem repeats (STRs) markers and 4 BRCA2 single-nucleotide polymorphisms (SNPs) covering 1.34 Mb of chromosome 13 surrounding the c.2808_2811del BRCA2 mutation. Primer sequences, Abbreviations: BC, breast cancer; ECL, East Castilla y León; SNP, singlenucleotide polymorphism; SoS, South of Spain; STR, short tandem repeat; WCL, West Castilla y León.
order of markers and physical distances among D13S260, D13S1699, D13S1698, D13S1697, D13S171, D13S1695 and D13S1694 were obtained from the Ensembl Genome Browser (21) . PCR products of STRs were generated using fluorescently labeled primers and subsequently electrophoresed on an ABI3130 sequencer (Applied Biosystems, Carlsbad, CA). Analysis was performed with the GeneMapper software v.3.7 (Applied Biosystems). Additionally, four BRCA2 SNPs: rs766173 (c.865A > C), rs144848 (c.1114C > A), rs1801406 (c.3396A > G) and rs543304 (c.3807T > C) were typed by TaqMan assays in a 7500 Real Time PCR System (Applied Biosystems).
Estimation of the mutation age
We used the Disequilibrium Mapping using Likelihood Estimation (DMLE) method (22) to estimate the mutation age. For this purpose, genotypes from 75 control individuals were submitted to the Phase v2.1 software to predict their 
Patient CN-59 had cervix carcinoma at 38 years. Number of bilateral BC cases is indicated in bold. ADx, age of diagnosis; bil, bilateral breast cancer; BOC, breast and ovarian cancer; CNS, central nervous system; CRC; colorectal cancer; MBC, male breast cancer; NHL, non-Hodgkin lymphoma; OC, ovarian cancer. BRCA2 3036delACAA is located in a mutation hotspot haplotypes and estimate their frequencies (Supplementary Table S1 , available at Carcinogenesis Online). Then the phased data together with the inferred consensus carrier haplotype of 46 families and the two more prevalent haplotypes were independently introduced into the DMLE program, which calculated the mutation age. Population growth rate (r) was estimated by the formula:
, where g is the number of generations between two time points, t 1 is the population size in 2010 (47 million) and t 0 the ancestral population size. We used demographic data (INe: Population Census) (23) of two different years for t 0 : 1594 (~8.2 million) or 1857 (~15 million), and g was estimated in 16.6 and 6.12 generations, respectively (considering 25 years per generation). Thus, r was estimated to be 0.124 and 0.190 for 1594 and 1857 data, respectively.
Random mutagenesis DNA of a control individual was amplified with Phusion Hot Start II HighFidelity DNA Polymerase (Thermo Fisher Scientific, Waltham, MA) and primers containing a 5′-tail with a restriction site (underlined) either for EcoRI (forward, 5′-CACACAGAATTCAGAGGCAAAGAATCATACAAA-3′) or for XhoI (reverse, 5′-CACACACTCGAGTTGGAAAATAACATCTGAGGG-3′ (923 bp, c.2359-c.3281). After restriction enzyme digestion, insert and plasmid pBluescript II KS (Stratagene, La Jolla, CA) were ligated with the FastLink DNA Ligation Kit (Epicentre, Madison, WI) to transform Escherichia coli DH5α cells. Random mutagenesis was carried out with the Genemorph II EZClone Domain PCR mutagenesis kit (Agilent, Santa Clara, CA). A PCR fragment (megaprimer) of 419 bp (c.2610-c.3028) was generated with nested BRCA2 primers 11E-Fw, 5′-TTCAAAAATAACTGTCAATCC-3′, and 11F-Rev, 5′-TGAAGCTACCTCCAAAACTGT-3′, and the error prone Mutazyme-II DNA polymerase. Mutant PCR products serve as megaprimers for the EZClone reaction during which they are denatured and annealed to the original plasmid and extended with a high-fidelity DNA polymerase. Then, the reaction was treated with DpnI, specific of methylated sequences, to eliminate the wild-type plasmid that had been used as template. XL10-Gold ultracompetent cells (Agilent) were transformed with 1.5 µl of the EZClone reaction following the manufacturer's protocol and were plated in Luria Broth agar (Sigma-Aldrich, St Louis, MO) plates with ampicillin: 100 µg/ml, X-Gal: 40 µg/ml and isopropyl β-d-1-thiogalactopyranoside: 0.1 mM. Seventy-five different colonies were picked individually and grown in liquid Luria Broth medium to purify plasmids with the Pure Yield™ Miniprep system (Promega, Madison, WI). Each clone was sequenced with BRCA2 primers 11E-Fw and 11F-Rev to characterize the generated mutations.
Sequence variation nomenclature Nomenclature of DNA variants followed the current guidelines of the Human Genome Variation Society (24) where nucleotide +1 is the A of the ATG translation initiation codon of the BRCA2 complementary DNA sequence NM_000059.1.
Results
We have analyzed seven STR and four SNP markers in a total of 51 families, one of them of British origin, harboring the c.2808_2811del mutation. Of these, at least two carrier relatives were tested in 37 families, whereas only the index case was available in other 14 families. Three different haplotypes were assigned to c.2808_2811del-positive families; except for families CN-428 and CN-565 that could not be successfully classified (Figure 1) . The geographical origin of the families and the corresponding haplotypes are shown in Figure 2 The most prevalent disease in carriers was BC with 62 cases (Table I) , 9 of which were bilateral and 2 were male BC cases. The medium age for BC cases was 43 years (range: 26-82), whereas for ovarian cancer, it was 58 years (49-69). Remarkably, 70 carriers (45 females and 25 males) were asymptomatic, although 60% of them (41/70) were aged <40 years (Supplementary Table S2 , available at 
Dating the origin of the mutation
The results were population growth rate depending, and the oldest demographic data in Spain were in year 1594, but they were not reliable until 1857. Accordingly, we used both records to calculate the Spanish population growth rate (r). The two main haplotypes and the complete set of 46 families with recognizable haplotype were submitted independently to DMLE analysis using the two r data (0.124 or 0.190; Supplementary Figure S1 , available at Carcinogenesis Online). Another key parameter in this software is the proportion of population sampled. The frequency of BRCA2 mutations in breast and ovarian cancer patients is 1-3% (25), thus we obtained 0.000217 assuming that 2% of 47 million people in Spain is a mutation carrier. In the whole set of 46 Spanish families, DMLE estimated a mutation age range between 72 and 110 generations (r = 0. Therefore, the mutation associated with ECL and WCL haplotypes could be dated on average ~55 generations ago (about 1375 years, in the VI-VII century during the Visigothic Kingdom; Supplementary Figure S1 , available at Carcinogenesis Online) when we used the most reliable estimation (0.190). Finally, mutation age of SoS haplotype could not be calculated as there had been collected only six families. However, all of them shared a common haplotype in 10 out of 11 markers, suggesting a more recent origin than the other two haplotypes.
Random mutagenesis
The absence of a unique ancestral haplotype as well as the identification of one de novo c.2808_2811del (14) suggested that this sequence was a mutation hotspot. It has been reported that mutations occur non-randomly since they are preferentially located in vulnerable stem-loops structures (17) . The DNA secondary structure of a 419-nucleotide region spanning this mutation was predicted with the Quikfold software (26, 27) . We found a total of 14 stem-loops structures (Supplementary Figure S2 , available at Carcinogenesis Online) where 82 mutations of the databases were mapped (Supplementary  Table S3 , available at Carcinogenesis Online). Forty-two out of them (51.2%) were positioned in single-stranded loops or bulges that represent 41.6% of the analyzed sequence (157/377 nucleotides, excluding primer sequences), and seven variants were placed in the same loop of mutation c.2808_2811del within a complex double-hairpin loop structure, sustaining that this structure may be a mutation hotspot.
With a view to investigating this hypothesis, we designed a random mutagenesis experiment over a fragment surrounding c.2808_2811del. Seventy-five different clones were sequenced, 48 of which contained one (21 clones) or two or more (27 clones) DNA variants. We identified 86 different DNA changes, 3 of which were recurrent and were found twice in independent clones: c.2683G > A, c.2771A > G and c.2957dup (Supplementary Table S3 , available at Carcinogenesis Online). Seven mutations were single nucleotide deletions, 1 was a single nucleotide insertion (c.2957dup) and 78 were nucleotide substitutions. In addition, three mutations reported in the mutation databases were replicated in the random mutagenesis experiment: c.2680G > A, c.2944del and c.2957dup (twice, see above). Other 20 variants affected identical positions of databases variants although they consisted of different nucleotide changes. Of BRCA2 3036delACAA is located in a mutation hotspot all changes produced, 53/86 (61.6%) were located into the stem-loops predicted by Quikfold ( Figure 3) . Remarkably, random mutagenesis generated five mutations in the double-hairpin loop (7) of the c.2808_2811del mutation, including a single-nucleotide substitution in position 2808 (c.2808A > G). The highest incidence of mutations was found in hairpin 8 with 1 mutation every 1.1 nucleotide (Table II) . Hairpins 4, 5 and 7 and intersequence 4 were also especially vulnerable to mutations with 1 mutation every 1.7-1.8 nucleotides.
Discussion
Multiple origins of c.2808_2811del
We found three different haplotypes linked to the mutation, which were correlated with the geographic distribution of families. Patients from Castilla y León were distributed into two haplotypes, which basically corresponded to the west and east areas of this region. Both areas had differences in the mutational spectrum of the BRCA genes (11,28), supporting two different genetic backgrounds and therefore two independent mutational events. The alternative hypothesis is the existence of a unique genetic origin that might have been originated either by a double recombination event between c.2808_2811del-rs1801406-rs543304 or by a de novo mutation at nucleotide c.3396 (A to G, rs1801406; Figure 1 ). Both options seem unlikely, since, first, rs1801406 was only 588 nucleotides downstream the deletion and 411 bp upstream rs543304 (totaling 999 bp), too close to undergo two crossovers; and second, the mutation rate of single-nucleotide variants in the human genome has been recently estimated in 1. (14) and an African BC patients without familial antecedents (13) give further support to multiple historical occurrences of c.2808_2811del. Indeed, one of our patients (a 32-year-old BC patient) was suspected to carry a de novo c.2808_2811del mutation, because none of the parents was a mutation carrier. Unfortunately, the haplotype construction cannot be performed because DNA patient sample was depleted. All the data presented here support that at least three different mutational events took place to originate c.2808_2811del so that this sequence could be a mutation hotspot.
Interestingly, c.2808_2811del was not previously reported in Sephardic Jewish BC patients (30) despite almost 20% of Y-STR haplotypes of the Iberian Peninsula and Balearic Island are of Sephardic origin (31) . This might be due to the small sample size of the first report (only 16 patients) and the low frequency of the Sephardic ancestry in Castilla y León (east: 2.5%; west: 12.9%) where c.2808_2811del probably arose (major haplotypes: ECL and WCL). Surprisingly, a putative founder BRCA1 mutation in Sephardic BC patients, c.5123C > A (p.A1708E) (30) , is precisely the most prevalent BRCA1 mutation in Castilla y León (12.2% of BRCA1 + families; data not shown) and the rest of Spain (11.3% on average) (9) , suggesting that its genetic origin requires further investigation.
In earlier reports, we estimated mutation age with a method based on the linkage disequilibrium due to recombination between the nearest recombinant marker and the mutation (28, 32, 33) . This calculation was impossible to conduct in c.2808_2811del families because the ancestral allele was more frequent in non-carrier chromosomes than in mutation carriers in all cases. In this report, we estimated by DMLE that the mutation arose in Spain ~58 generations ago (1450 years), dating the mutation back to the 6th century during the Visigothic Kingdom with a range between 49 and 73 generations, and began to spread to the rest of Spain. Mutation age was previously estimated in ~80 generations with the maximum likelihood method in 11 families from different countries, including Spain (12) .
Mutation hotspot
It was reported that the most hypermutable nucleotides of the TP53 gene are located in secondary structures called hairpin loops and bulges (17) . These structures contain regions of single-stranded DNA with unpaired or mispaired bases that are more vulnerable to mutation because they are exposed to endogenous (e.g. metabolites or DNA polymerase errors) or exogenous mutagens (15) . Furthermore, Quikfold data illustrate a complex structure that the polymerase might not copy properly (Figure 3 ), leading to different DNA changes around this position (26, 34) . Moreover, the most reported sequence changes in the BIC database and Universal Mutation Database between nucleotides c.2610-c.3028 were precisely this mutation (c.2808_2811del, 199 records in the BIC database and Universal Mutation Database) and c.2803G > A (151 records), both in the single-stranded portion of this loop. Random mutagenesis created five different mutations in the predicted arrangement with even a single-nucleotide substitution in position c.2808. We previously showed that two founder mutations of Castilla y León, BRCA1 c.5153-1G > A and BRCA2 c.5146_5149delTATG, were also located in such secondary structures (28) . Altogether these data, we can conclude that the double-hairpin structure of c.2808_2811del is a mutation hotspot. It is also worth mentioning that hairpin loops 4, 5 and 8 have a high incidence of reported and 'artificial' mutations (Table II) , suggesting that they could also be hotspots. However, the mutagenesis experiment did not generate c.2808_2811del as Mutazyme-II polymerase only introduced insertions and deletions of one nucleotide despite we almost doubled the indel rate described with this polymerase (10.1 versus 5.5%).
In any case, we should be cautious when interpreting these results since this assay does not reproduce the physiological conditions: first, Mutazyme-II is a modified prokaryotic polymerase; second, the supercoiled structure of the plasmid where the template is cloned may influence this process; and third, the genomic and nucleosomal contexts may also play a role in the natural phenomenon of mutagenesis. Twenty different variants (three of them in two independent clones) of the mutagenesis experiment affected the same positions of reported variants, but they consisted of different nucleotide changes, and three mutations produced the same nucleotide change: one single-nucleotide substitution (c.2680G > A), one insertion (c.2957dup in two independent clones) and one deletion (c.2944del). Curiously, none of these three variants was placed in hairpin loops, suggesting that their occurrence is not probably related to the secondary structure of DNA. On the other hand, the most prevalent mutations of BRCA1 (c.68_69del) and BRCA2 (c.5946delT), both of Ashkenazi origin, are located in a hairpin loop structure and in a complex hairpin arrangement with multiple loops, respectively (Figure 4) . Interestingly, c.68_69del has been proven to have at least three founder effects (35, 36) , suggesting that this sequence is also a mutation hotspot. The observation of a recurrent BRCA mutation with multiple origins has also been documented in BRCA2 c.8537delAG that was found in distinct populations with three differentiated haplotypes (37) . The authors suggested that the presence of repetitive sequences could allow for mismatching during replication. As expected, BRCA2 c.8537delAG also lies in a large loop (Figure 4 ).
In conclusion, the presence of several haplotypes linked to c.2808_2811del indicated that at least three independent events occurred. This might due to the presence of a mutation hotspots in this region that would justify its high frequency worldwide. This sequence lies within a double-hairpin loop structure that we postulate as a mutation hotspot. The identification of recurrent mutations in a specific population allows the redefinition of the genetic screening strategy as well as a more accurate estimation of the risk associated with this mutation.
Supplementary material
Supplementary Tables S1-S3 and Figures S1 and S2 can be found at http://carcin.oxfordjournals.org/
